SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $150,000
in Losses from Investment in Amarin Corporation plc to Contact Brower Piven
Before the January 3, 2014 Lead Plaintiff Deadline
STEVENSON, Md. -- November 19, 2013
Brower Piven, A Professional Corporation announces that a class action lawsuit
has been commenced in the United States District Court for the District of New
Jersey on behalf of purchasers of Amarin Corporation plc (“Amarin” or the
“Company”) (NasdaqGM: AMRN) common stock during the period between July 9,
2009 and October 15, 2013, inclusive (the “Class Period”).
If you have suffered a net loss from investment in Amarin Corporation plc
common stock purchased on or after July 9, 2009, and held through the
revelation of negative information on October 16, 2013, as described below, at
no cost to you, you may obtain additional information about this lawsuit and
your ability to become a lead plaintiff by contacting Brower Piven at
www.browerpiven.com, by email at email@example.com, by calling
410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley
Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined
experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply
to be appointed lead plaintiff no later than January 3, 2014 and be selected
by the Court. The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from investment in
the Company during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants’ failure to disclose during the Class
Period the true prospects for approval of the Company’s Vascepa drug for the
ANCHOR indication by the U.S. Food and Drug Administration (“FDA”). According
to the complaint, following an October 16, 2013 vote by an advisory panel to
the FDA that Vascepa not be approved for use in a broader patient population
until results from an additional study had been analyzed, the value of Amarin
shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice. You
need take no action at this time to be a member of the class.
Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
Press spacebar to pause and continue. Press esc to stop.